Conference Reports for NATAP

Back

The Liver Meeting AASLD 2024 Nov 15-19, San Diego, CA   This information is brought to you by NATAP and is not sponsored by, nor a part of, the American Association for the Study of Liver Diseases or The Liver Meeting® or The Liver Meeting Digital Experience ™     CHARACTERIZATION OF THE DIRECT ANTIVIRAL EFFECT OF REP 2139 IN 2D AND 3D HDV INFECTION MODELS - (12/11/24)   Safety and efficacy of REP 2139-Mg in hepatitis D patients: reporting of extended follow-up data from the international compassionate use program - (12/11/24)   Bemnifosbuvir Does Not Alter Cardiac Repolarization in Healthy Participants: Results from a Thorough QT Study - (12/11/24)   Multiscale modeling of lead-in results from a phase 2 study of an 8-week combination regimen of Bemnifosbuvir and Ruzasvir in patients with chronic hepatitis C virus infection - (12/11/24)   Bemnifosbuvir Poses High Barrier for Resistance in Both Preclinical and Phase 1b Monotherapy Studies - (12/11/24)   Impact of elafibranor on fatigue in patients with primary biliary cholangitis: Interim results from the long-term open-label extension of the ELATIVE® trial - (12/07/24)   Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis: Pooled Interim Results for up to 3 Years From the ASSURE Study - (12/07/24)   Attenuation, Near Resolution, and Prevention of Pruritus in Patients With Primary Biliary Cholangitis Treated With Seladelpar: A Secondary Analysis of Patterns of Pruritus Change in the RESPONSE Trial - (12/07/24)   Long-term efficacy and safety of elafibranor in primary biliary cholangitis: Interim results from the open-label extension of the ELATIVE® trial up to 3 years - (12/07/24)   Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis and Compensated Cirrhosis in the Phase 3 Placebo-Controlled RESPONSE Trial - (12/07/24)   One-year treatment with elafibranor in the phase III ELATIVE® trial improves GLOBE and UK-PBC prognostic scores - (12/07/24)   Volixibat for Cholestatic Pruritus in Primary Biliary Cholangitis: An Adaptive, Randomized, Placebo-controlled Phase 2b Trial (VANTAGE): Interim Results - (12/07/24)   HIGH PREVALENCE AND LOW AWARENESS OF CHRONIC LIVER DISEASE AMONG SEXUAL MINORITY MEN IN LOS ANGELES - (12/04/24)   Akero Therapeutics to Showcase New Analyses of Phase 2b [efruxifermin] HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024 - (12/04/24)   Efruxifermin significantly reduced proportion of participants with at-risk MASH and led to near-complete histological disease reversal at week 96 in the HARMONY study - (12/04/24)   Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting 2024 - (12/04/24)   Resmetirom effects on NASH with liver fibrosis in patients with NASH genetic risk alleles - (12/04/24)   Effect of Resmetirom or Placebo in NASH Fibrosis Patients With <5% or ≥5% Weight Loss and/or on Baseline GLP-1 Therapy in the MAESTRO-NASH 52-Week Serial Liver Biopsy Study - (12/04/24)   SEVEN-YEAR FOLLOW-UP OF A PREDOMINANTLY HISPANIC PATIENTS WITH SIGNIFICANT STEATOSIS AT A PRIMARY CARE CLINIC: UPDATE ON THE SOUTH BAY COHORT - (12/04/24)   Hepatitis C Treatment Uptake Differs by Gender Among a Commercially Insured Population in the United States - (12/04/24)   Factors associated with long-term risk of liver-related and non-liver-related death after sustained virologic response in patients with hepatitis C virus treated with direct-acting antiviral - (12/04/24)   Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis Delta Receiving Bulevirtide With or Without Pegylated Interferon Alfa-2a in MYR204 - (12/04/24)   HBV/HDV Genotypes in HBV/HDV-Coinfected Patients in the United States - (12/04/24)   Efficacy and Safety of Tobevibart (VIR-3434) Alone or in Combination With Elebsiran (VIR-2218) in Participants With Chronic Hepatitis Delta Virus Infection: Week 24 Primary Endpoint Analysis From the Phase 2 SOLSTICE Trial - (12/03/24)   Efficacy and Safety of Bulevirtide Monotherapy for Chronic Hepatitis Delta: Posttreatment Results Through 48 Weeks After the End of Treatment From an Interim Analysis of a Randomized Phase 3 Study, MYR301 - (12/03/24)   Similar Rates of Biochemical Response Are Observed Across Virologic Response Categories Over 96 Weeks of Bulevirtide Monotherapy in Patients With Chronic Hepatitis Delta - (12/03/24)   Real world outcomes of Hepatitis Delta patients with mild or moderate fibrosis - (12/03/24)   Characteristics and Antiviral Treatment Patterns Among US Adults With Laboratory-Confirmed Hepatitis Delta Virus vs Hepatitis B Virus Monoinfection - (12/03/24)   BULEVIRTIDE MONOTHERAPY MAY REDUCE LIVER DECOMPENSATION IN PATIENTS WITH HDV-RELATED CIRRHOSIS: A CASE-CONTROL STUDY WITH PROPENSITY SCORE WEIGHTED ANALYSIS - (12/03/24)   Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide 2 mg Once Daily for 6 Days in Participants With Moderate and Severe Hepatic Impairment and in Matched Control Participants With Normal Hepatic Function - (12/03/24)   Patients With Hepatitis Delta Virus Have a Higher Risk of Disease Progression Than Patients With Hepatitis B Virus Monoinfection: Results From a Large Healthcare Provider in Israel - (12/03/24)   Patient-Reported Outcomes Among Patients With Chronic Hepatitis Delta Treated With Bulevirtide 2 mg: A Long-Term Analysis of the Phase 3 MYR301 Trial at 144 Weeks - (12/03/24)   Association of Hepatitis Delta Virus (HDV) Infection and Hepatocellular Carcinoma, Decompensation, All-cause and Liver-Related Death in a US National Cohort - (12/03/24)   LONG-TERM BULEVIRTIDE MONOTHERAPY IN PATIENTS WITH HDV-RELATED COMPENSATED CIRRHOSIS: EFFECTIVENESS, SAFETY AND CLINICAL OUTCOMES FROM THE RETROSPECTIVE MULTICENTER EUROPEAN STUDY (SAVE-D) - (12/03/24)   BJT-778, anti-HBsAg monoclonal antibody, achieved 100% virologic response in subjects with chronic hepatitis D (CHD): phase 2 study results - (12/03/24)   Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program - (12/03/24)   Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency - (12/03/24)   Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program - (12/03/24)   Tobevibart (VIR-3434) and Elebsiran (VIR-2218) With or Without Pegylated Interferon Alfa-2a for the Treatment of Chronic HBV Infection: End of Treatment Results After 48 Weeks of Therapy (MARCH Study) - (12/03/24)   Tobevibart (VIR-3434) and Elebsiran (VIR-2218) With or Without Pegylated Interferon Alfa-2a for the Treatment of Chronic HBV Infection: End of Treatment Results After 48 Weeks of Therapy (MARCH Study) - (12/02/24)   Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting - (12/02/24)   Efficacy and Safety of Elebsiran and PEG-IFNα Combination Therapy vs PEG-IFNα in Participants With Chronic HBV Infection: Preliminary EOT Results From ENSURE Study - (12/02/24)   Semi-mechanistic PK/PD modeling and simulation of sequential siRNA and bepirovirsen treatment predicts added benefit in HBsAg response in support of Phase 2b dose selection - (12/02/24)   Preliminary Antiviral Efficacy and Safety of Repeat Dosing of Imdusiran (AB-729) Followed by VTP-300 With or Without Nivolumab in Virally-Suppressed, Non-Cirrhotic Subjects With Chronic Hepatitis B (CHB) - (12/02/24)   Evaluating the safety and efficacy of SOF/VEL treatment and prophylactic use of TAF in patients with chronic HBV/HCV coinfection: A multicenter study - (12/02/24)   ROBUST HEPATITIS B SURFACE ANTIGEN REDUCTION BY HT-101 IN CHRONIC HEPATITIS B PATIENTS: RESULTS FROM A PHASE Ι B STUDY - (12/02/24)   A randomized controlled trial of tenofovir alafenamide prophylaxis in HBsAg-positive rheumatic patients treated with biologics - (12/02/24)   LONG-TERM OUTCOMES OF BASELINE GREY-ZONE PATIENTS WITH HBeAg-NEGATIVE CHRONIC HEPATITIS B VIRUS INFECTION IN GREECE - (12/02/24)   Expected 8-Week Prenatal vs 12-Week Perinatal TAF Prophylaxis to Prevent HBV-MTCT: A Multicenter, Prospective, Open-label, Randomized Controlled Trial - (12/02/24)   Kinetics of Hepatitis B Surface Antigen Loss Following 8 Years of Tenofovir-Based Treatment in Hepatitis B e Antigen-Negative and Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B - (12/02/24)   MONOTHERAPY WITH THE CAPSID ASSEMPLY MODULATOR, ALG-000184, RESULTS IN HIGH VIRAL SUPPRESSION RATES IN UNTREATED HBEAG+ AND HBEAG- SUBJECTS WITH CHRONIC HEPATITIS B VIRUS INFECTION - (12/02/24)   RAPID START-UP OF A FIELD-BASED HEPATITIS C ELIMINATION PROGRAM ENABLED BY STATE FUNDED 340B INITIATIVE, Specialized Mobile Outreach - (11/26/24)   Characteristics and Treatment Patterns of Transgender Men and Women Living With Hepatitis C in the United States - (11/26/24)   PREVALENCE AND RISK FACTORS FOR HCC AMONG PATIENTS WITH CURENT AND PRIOR HCV IN A REAL-WORLD COHORT IN THE POST-DAA ERA - (11/26/24)   Hepatitis C Treatment Uptake Differs by Gender Among a Commercially Insured Population in the United States, young women 35% less likely to start DAA treatment - (11/26/24)   Delineating gaps in the cascade of care among pregnant women with HCV: An observational retrospective analysis of real-world data on a commercially insured cohort in the US - (11/26/24)   The SVR10K study: Real-World Data with Pangenotypic Direct-Acting Antivirals (SOF/VEL) Across Multiple Diverse Regions - (11/26/24)   Characteristics of persons treated for hepatitis C in the United States, 2014-2023 - (11/26/24)   Hepatic steatosis in chronic hepatitis C affects the risk of hepatocellular carcinoma mainly in women - (11/26/24)   Boston Pharmaceuticals to Announce Positive Phase 2 Data on Efimosfermin Alfa (BOS-580) in F2/F3 MASH During Late-Breaking Oral Presentation at AASLD 2024, The Liver Meeting - (11/26/24)   Phase 3 ESSENCE trial: Semaglutide in metabolic dysfunction-associated steatohepatitis - (11/26/24)   Hepatocellular Carcinoma Risk Reduction Associated With Antiviral Treatment in Patients With Noncirrhotic Chronic Hepatitis B: A Comparative Meta-Analysis - (11/26/24)   TENOFOVIR ALAFENAMIDE VERSUS TENOFOVIR DISOPROXIL FUMARATE IN CHRONIC HEPATITIS B: LIVER-RELATED CLINICAL OUTCOMES AND SUBGROUP ANALYSIS BY LIVER CIRRHOSIS STATUS - (11/26/24)   Gaps in Hepatitis B Laboratory Monitoring Among an Ethnically Diverse Cohort of Adults with Treatment-Naïve Chronic Hepatitis B Infection in the United States - (11/26/24)   Gender-Specific Disparities in Receiving Antiviral Therapy Among Treatment-Eligible Adults with Chronic Hepatitis B Infection Across Three Safety-Net Health Systems in the United States - (11/26/24)   Evaluating Gaps and Disparities in Hepatitis B Treatment among US Adults: A Real-World Analysis using a Nationwide Electronic Health Records Database - (11/26/24)   Characterization of Changes in Noninvasive Fibrosis Markers Over 8 Years of Tenofovir-Based Treatment in Patients With Chronic Hepatitis B Enrolled in Two Phase 3 Trials - (11/26/24)   Risk of Advanced Liver Disease Among Individuals With Hepatitis B Virus Infection and Low-Level Viremia Compared to Individuals With No Evidence of Hepatitis B Virus Infection - (11/26/24)   NORMALIZATION OF ALANINE AMINOTRANSFERASE BY LOWER UPPER LIMIT OF NORMAL DURING ANTIVIRAL TREATMENT WAS ASSOCIATED WITH LOWER RISK OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B - (11/26/24)   THE CURRENT BURDEN OF HEPATITIS B IN THE UNITED STATES: A STATE, TERRITORIAL, AND COUNTY ANALYSIS -THE IMPACT OF IMMIGRATION, 2021 - (11/26/24)   Glecaprevir/Pibrentasvir in Chronic HCV: An Integrated Analysis of Patients on Multiple Concomitant Medications - (11/25/24)   Effectiveness of Glecaprevir/Pibrentasvir for 8 Weeks in People Taking Antipsychotics, Buprenorphine/Naloxone, or Illicit Drugs - (11/25/24)   A COMPARISON OF SOFOSBUVIR/VELPATASVIR (S/V) AND GLECAPREVIR/PIBRENTASVIR (G/P) FOR THE TREATMENT OF HCV INFECTION AMONG HCV-INFECTED PEOPLE WHO USE DRUGS (PWUD) - (11/25/24)   A Multicenter, Single-Arm, Prospective, Phase 3b Study to Evaluate Safety and Efficacy of Glecaprevir/Pibrentasvir 8-Week Treatment in Adults With Acute Hepatitis C Virus Infection - (11/25/24)   Safety, Tolerability, and Outcomes of SofosbuviR/Velpatasvir in Treatment of Chronic Hepatitis C Virus during Pregnancy: Interim results from the STORC study - (11/25/24)   HEPATITIS C MANAGEMENT OF WOMEN IN THE THIRD TRIMESTER OF PREGNANCY IN LA BODEGA - (11/25/24)   Same Day and Rapid Start HCV Management in La Bodega Clinic - (11/25/24)   Liver stiffness as a predictive factor for hepatocellular carcinoma development after sustained virologic response by direct-acting antivirals for chronic hepatitis C; HCC can occur after SVR at low rates - (11/25/24)   LONG TERM OUTCOME AMONG HCV-INFECTED PEOPLE WHO USE DRUGS (PWUD) SUCCESSFULLY TREATED FOR HCV INFECTION WITH GLECAPREVIR/PIBRENTASVIR (G/P) - (11/25/24)   SUCCESSFUL PERFORMANCE OF THE XPERT® HCV TEST FOR POINT OF CARE DETECTION OF HCV RNA IN A CLIA-WAIVED SETTING - (11/25/24)   COMMUNITY POP-UP CLINIC: CASCADE OF CARE AND HCV TREATMENT OF VANCOUVER'S INNER-CITY PWID POPULATIONS - (11/25/24)   Association of MASLD Phenotypes with Liver Fibrosis in Hepatitis C: The Role of Cardiometabolic Risk Factors - (11/25/24)   Sofosbuvir/Velpatasvir Effectiveness in Treating Chronic Hepatitis C Genotype 3: A Real-World Study in Xinjiang, China. - (11/25/24)   HCV REINFECTION AMONG PEOPLE WHO USE DRUGS (PWUD) TREATED FOR HCV INFECTION: A LONG-TERM REVIEW - (11/25/24)   Rapid Hepatitis C Test and Treat with Peer Support at Opioid Treatment Programs (RAPID HCV): A multicenter randomized control trial - (11/25/24)   A multicenter real world study of sofosbuvir/velpatasvir for HIV/HCV coinfected patients - (11/25/24)   CLINICAL PERFORMANCE EVALUATION OF THE XPERT® HCV TEST AT POINT OF CARE IN A MULTI-SITE PROSPECTIVE CLINICAL STUDY - (11/25/24)   Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024 - (11/07/24)